First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling PathwayMargit Hagel, Timothy J. Guzi|Cancer Discovery|2015Cited by 314
The Pan-RAF–MEK Nondegrading Molecular Glue NST-628 Is a Potent and Brain-Penetrant Inhibitor of the RAS–MAPK Pathway with Activity across Diverse RAS- and RAF-Driven CancersMeagan B. Ryan, Margit Hagel, Bradley Quade et al.|Cancer Discovery|2024Cited by 43
Supplementary Methods from The Pan-RAF–MEK Nondegrading Molecular Glue NST-628 Is a Potent and Brain-Penetrant Inhibitor of the RAS–MAPK Pathway with Activity across Diverse RAS- and RAF-Driven CancersMeagan B. Ryan, Margit Hagel, Bradley Quade et al.|Unknown|2024Cited by 1
Abstract A086: NST-628 is a novel molecular glue that inhibits signaling and pathway reactivation in oncogenic RAS-MAPK cancersBradley Quade, Michael Hale, Meagan B. Ryan et al.|Molecular Cancer Therapeutics|2023Cited by 1
Data from The Pan-RAF–MEK Nondegrading Molecular Glue NST-628 Is a Potent and Brain-Penetrant Inhibitor of the RAS–MAPK Pathway with Activity across Diverse RAS- and RAF-Driven CancersMeagan B. Ryan, Margit Hagel, Bradley Quade et al.|Unknown|2024Cited by 1